These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33818714)

  • 21. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Managing hepatocellular carcinoma across the stages: efficacy and outcomes of stereotactic body radiotherapy : A retrospective study.
    Mohamed AA; Berres ML; Bruners P; Lang SA; Trautwein C; Wiltberger G; Barabasch A; Eble M
    Strahlenther Onkol; 2024 Aug; 200(8):715-724. PubMed ID: 38689147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
    Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Kim JY; Yoo EJ; Jang JW; Kwon JH; Kim KJ; Kay CS
    Radiat Oncol; 2013 Jan; 8():15. PubMed ID: 23324259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.
    Yu JI; Park HC
    World J Gastroenterol; 2016 Aug; 22(30):6851-63. PubMed ID: 27570422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis.
    Sun J; Wang Q; Hong ZX; Li WG; He WP; Zhang T; Zhang AM; Fan YZ; Sun YZ; Zheng L; Duan XZ
    Hepatol Int; 2020 Sep; 14(5):788-797. PubMed ID: 32886334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.
    Kim JW; Seong J; Lee IJ; Woo JY; Han KH
    Oncotarget; 2016 Jun; 7(26):40756-40766. PubMed ID: 27213593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety.
    Lee SJ; Kim M; Kwak YK; Kang HJ
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2405-2414. PubMed ID: 34490584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma.
    Lee JW; Hwang SH; Kim DY; Han KH; Yun M
    Clin Nucl Med; 2017 Jan; 42(1):e35-e40. PubMed ID: 27775940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
    Liu HY; Lee YD; Sridharan S; Choong ES; Le H; Wang W; Khor R; Chu J; Oar A; Mott R; Smart J; Jenkins T; Anderson N; Cross S; Loo KF; Wigg A; Stuart K; Pryor D
    J Med Imaging Radiat Oncol; 2021 Jun; 65(3):365-373. PubMed ID: 33890425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
    Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
    BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT.
    Hou JZ; Zeng ZC; Wang BL; Yang P; Zhang JY; Mo HF
    Jpn J Clin Oncol; 2016 Apr; 46(4):357-62. PubMed ID: 26802166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A Case of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated Successfully with Multidisciplinary Therapy Including Preoperative Stereotactic Body Radiotherapy(SBRT)].
    Nishimura S; Tomokuni A; Kobayashi S; Asukai K; Akita H; Takahashi H; Yanagimoto Y; Takahashi Y; Miyoshi N; Sugimura K; Yamamoto K; Ohmori T; Ohue M; Yano M; Sakon M
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1650-1652. PubMed ID: 29394731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
    AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
    [No Abstract]   [Full Text] [Related]  

  • 37. Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching.
    Tang C; He Q; Feng J; Liao Z; Peng Y; Gao J
    Front Immunol; 2023; 14():1254158. PubMed ID: 37928530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
    Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombocytopenia: A prognostic factor for hepatocellular carcinoma patients with portal vein tumor thrombus after hepatectomy.
    Cheng YQ; Wang K; Zhang XP; Wei XB; Jiang YB; Hu YR; Mao FF; Guo WX; Shi J; Cheng SQ
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1214-1221. PubMed ID: 30402968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma.
    Byun HK; Kim HJ; Im YR; Kim DY; Han KH; Seong J
    Radiother Oncol; 2019 Apr; 133():1-8. PubMed ID: 30935563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.